Close Menu

NEW YORK (GenomeWeb) – Somalogic and DeCode Genetics announced today that they are collaborating on a proteomic analysis of up to 40,000 of DeCode's patient samples.

The analysis will use Somalogic's SomaScan platform, which measures the levels of 5,000 proteins using the company's Somamer affinity reagents. According to the firms, Reykjavik-based DeCode will use the data gathered through this analysis for drug discovery and development work, while Boulder, Colorado-based Somalogic will use the findings to develop clinical applications of the SomaScan platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis founds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.